events & presentations
-
Intellia Therapeutics – Company Overview
-
26th Annual Congress of the European Society of Gene and Cell Therapy: “Supra-therapeutic levels of transgene expression achieved in vivo by CRISPR/Cas9 mediated targeted gene insertion” – Oct. 2018
-
26th Annual Congress of the European Society of Gene and Cell Therapy: “Delivering on the therapeutic potential of CRISPR/Cas9: Development of an LNP-mediated genome editing therapeutic for the treatment of ATTR” – Oct. 2018
-
Genome Engineering: The CRISPR-Cas Revolution at Cold Spring Harbor Laboratory Presentation: “Development of NTLA-1001: First-in-Class, LNP-CRISPR/Cas9 Mediated Genome Editing Therapeutic for the Treatment of ATTR” – Aug. 2018
-
ASGCT Poster: “Rescue of Amyloid Deposition Phenotype After Single-Treatment CRISPR / Cas9 Gene Editing in a Humanized Mouse Model of ATTR” – May 2018
